Chuangxin International is an innovative biomedical enterprise with organoids as its core technology. It consists of the China-Europe Organoid Research Institute and a third-party clinical testing center. At present, Chuangxin has a number of organoid patents, and its business covers many provinces and regions across the country, mainly providing organoid culture detection systems and new drug research and development. As a pioneer in organoid technology and transformation, Chuangxin is committed to the three directions of clinical individualized treatment of organoids, drug research and development, and regenerative medicine, and builds a whole industry chain of organoids. Recently, Chuangxin International announced the completion of the Pre-B round of financing of RMB 100 million. This round of financing was led by Dachen Caizhi, followed by Guangzhou Financial Holdings, Guangzhou Development Zone Fund, Wanlian Securities, Zhonghe Anke, and Qudao Assets and other original investment institutions continued to make additional investments.
This article is reproduced from: https://www.itjuzi.com/investevent/13630862
This site is for inclusion only, and the copyright belongs to the original author.